Thailand

As of 2026, Thailand has solidified its status as a premier life sciences hub in Southeast Asia, driven by a sophisticated "Golden Year" of healthcare transformation and strategic government backing.

The nation is globally recognized for its robust pharmaceutical manufacturing capabilities, transitioning from a generic drug producer to a leader in Advanced Therapy Medicinal Products (ATMPs) and biotechnology.

Thailand's medical device sector is experiencing a massive boom, with a projected market value reaching $8.5 billion, fueled by high demand for diagnostics, minimally invasive surgery tools and smart hospital technologies.

The ecosystem is anchored by the Eastern Economic Corridor (EEC), where the Thailand Board of Investment (BOI) offers lucrative tax incentives and 100% foreign ownership to attract global R&D and precision medicine ventures.

Furthermore, Thailand is pioneering healthcare innovation through the world's first Halal Regenerative Medicine Ecosystem, merging cutting-edge stem cell research with ethical governance.

Academic excellence remains a cornerstone, with top-tier institutions like Mahidol and Chulalongkorn Universities driving genomic research and vaccine development.

With over 60 JCI-accredited hospitals, the country seamlessly integrates its world-renowned medical tourism with advanced digital health and AI-driven diagnostics.

This unique blend of translational science, clinical trial efficiency and a thriving longevity economy makes Thailand an indispensable partner for global life sciences investors.